Life Science Investing Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Life Science Investing Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Life Science Investing Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Significant Gold Discoveries Continue at Golden Gate - Drilling Hits 253.0m @ 1.5 g/t Au from Surface and Open in all Directions Ending in Mineralisation
Detailed Ground Gravity, Magnetic and Radiometric Surveys Refine Priority REE Targets at Desert Star Projects, California, USA
